Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients

Chen, Feng; Yang, Menghan; Song, Qingkun; Wu, Jiangping; Wang, Xiaoli; Zhou, Xinna; Yuan, Yunxia; Song, Yang; Jiang, Ni; Zhao, Yanjie; Zhou, Lei; Ren, Jun

doi:10.3892/mco.2017.1415

Cited by 8 publications

(8 citation statements)

References 29 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 129 Another study evaluated a DC+CIK combination therapy in a basket trial, and showed that DCs enhanced the activation of CIKs. 136 There is also evidence that a DC+CIK regimen can control tumor development and increase OS. 136 , 137 An in vitro study of HCC cells (BEL27402) compared to DC+CIK alone, sorafenib alone, and CIK alone, and DC+CIK with sorafenib, showed the greatest efficacy in the DC+CIK with sorafenib group.…”

Section: Cellular Therapies For Hccmentioning

confidence: 99%

Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future

Wei,

Dong,

2024

J Clin Transl Hepatol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common cancer, and the body’s immune responses greatly affect its progression and the prognosis of patients. Immunological suppression and the maintenance of self-tolerance in the tumor microenvironment are essential responses, and these form part of the theoretical foundations of immunotherapy. In this review, we first discuss the tumor microenvironment of HCC, describe immunosuppression in HCC, and review the major biomarkers used to track HCC progression and response to treatment. We then examine antibody-based therapies, with a focus on immune checkpoint inhibitors (ICIs), monoclonal antibodies that target key proteins in the immune response (programmed cell death protein 1, anti-cytotoxic T-lymphocyte associated protein 4, and programmed death-ligand 1) which have transformed the treatment of HCC and other cancers. ICIs may be used alone or in conjunction with various targeted therapies for patients with advanced HCC who are receiving first-line treatments or subsequent treatments. We also discuss the use of different cellular immunotherapies, including T cell receptor (TCR) T cell therapy and chimeric antigen receptor (CAR) T cell therapy. We then review the use of HCC vaccines, adjuvant immunotherapy, and oncolytic virotherapy, and describe the goals of future research in the development of treatments for HCC.

show abstract

Section: Cellular Therapies For Hccmentioning

confidence: 99%

Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future

Wei,

Dong,

2024

J Clin Transl Hepatol

View full text Add to dashboard Cite

show abstract

“…At 1 year, 29/33 (88%) patients in the CIK-treated group and 23/31 (68%) in the control group were recurrence-free [33]. DCs can promote CIK activation, and combined DC-CIK therapy has been tested in an oncology basket study [34]. DC-CIK alone was reported to control tumour growth and improve OS [34,35].…”

Section: Combinatorial Approaches: Ciks + Tacementioning

confidence: 99%

“…DCs can promote CIK activation, and combined DC-CIK therapy has been tested in an oncology basket study [34]. DC-CIK alone was reported to control tumour growth and improve OS [34,35]. In combination with Sorafenib, DC-CIK showed activity against the HCC target cell line BEL27402 in preclinical models, with improved cytotoxicity compared with DC-CIK alone, sorafenib alone and CIK cells alone (p < 0.01) [36].…”

Section: Combinatorial Approaches: Ciks + Tacementioning

confidence: 99%

Novel Cellular Therapies for Hepatocellular Carcinoma

Roddy

Meyer

Roddie

2022

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Most patients present with advanced disease, and current gold-standard management using tyrosine kinase inhibitors or immune checkpoint inhibitors (ICIs) offers modest clinical benefit. Cellular immune therapies targeting HCC are currently being tested in the laboratory and in clinical trials. Here, we review the landscape of cellular immunotherapy for HCC, defining antigenic targets, outlining the range of cell therapy products being applied in HCC (such as CAR-T and TCR-T), and exploring how advanced engineering solutions may further enhance this therapeutic approach.

show abstract

“…Qiu et al (2016) showed that the combination of CIK cells and DCs pulsed with an antigenic α-1,3-galactosyl epitopeenhanced lymphoma cell membrane could provide an effective immunotherapy for B-cell lymphomas [44]. Chen et al (2016) also evaluate the clinical efficacy of DC-CIK cell therapy in patients with advanced cancers, including lymphoma [45]. The study reported that DC-CIK infusions were able to positively alter the ratios of T-cell subsets by increasing the CD3+CD8+ (cytotoxic T cells, CTL) and CD3+CD56+ (NKT) subsets, and decreasing the CD4+CD25+ subsets without serious side effects.…”

Section: Clinical Studies On Dc-cik Cellsmentioning

confidence: 99%

Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials

Zhang

Sharma

Weiher

et al. 2021

Cancers

View full text Add to dashboard Cite

Cancer is a complex disease where resistance to therapies and relapses often pose a serious clinical challenge. The scenario is even more complicated when the cancer type itself is heterogeneous in nature, e.g., lymphoma, a cancer of the lymphocytes which constitutes more than 70 different subtypes. Indeed, the treatment options continue to expand in lymphomas. Herein, we provide insights into lymphoma-specific clinical trials based on cytokine-induced killer (CIK) cell therapy and other pre-clinical lymphoma models where CIK cells have been used along with other synergetic tumor-targeting immune modules to improve their therapeutic potential. From a broader perspective, we will highlight that CIK cell therapy has potential, and in this rapidly evolving landscape of cancer therapies its optimization (as a personalized therapeutic approach) will be beneficial in lymphomas.

show abstract

Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients

Cited by 8 publications

References 29 publications

Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future

Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future

Novel Cellular Therapies for Hepatocellular Carcinoma

Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials

Contact Info

Product

Resources

About